Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC)

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Dec 20

PMID 30564559

Citations 1

Authors

Kedar Kirtane

Cristina P Rodriguez

Affiliations

Soon will be listed here.

Abstract

Patients who undergo upfront curative intent resection for locally advanced squamous cell carcinomas and who have adverse pathologic features benefit from adjuvant therapy. Concurrent cisplatin based chemoradiation is an established standard of care endorsed by national guidelines. Controversy now exists on the applicability of this strategy to the good risk human papilloma virus (HPV) related oropharynx cancer (OPC) patient. Ongoing clinical studies are exploring therapeutic de-escalation in the postoperative setting for this distinct patient population. The introduction of immune checkpoint inhibitors to the therapeutic armamentarium for recurrent/metastatic head and neck cancer patients has led to clinical investigation of incorporation of PD-1 inhibition in the postoperative setting.

Citing Articles

Postoperative Radiation With or Without Concurrent Chemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma With Multiple Intermediate Risks: A Propensity Score-Matched Study.

Leewiboonsilp T, Jianpinijnan C, Thokanit N, Pattaranutaporn P, Ngamphaiboon N Cancer Med. 2025; 14(5):e70746.

PMID: 40052649 PMC: 11886883. DOI: 10.1002/cam4.70746.

Identify characteristics of Vietnamese oral squamous cell carcinoma patients by machine learning on transcriptome and clinical-histopathological analysis.

Duong H, Huynh N, Nguyen C, Le L, Nguyen K, Nguyen H J Dent Sci. 2025; 19(Suppl 1):S81-S90.

PMID: 39807441 PMC: 11725156. DOI: 10.1016/j.jds.2024.08.013.

Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.

Liao J, Yang Z, Azarbarzin S, Cullen K, Dan H Head Neck. 2024; 46(5):1126-1135.

PMID: 38429897 PMC: 11003831. DOI: 10.1002/hed.27718.

References

Pignon J, Bourhis J, Domenge C, Designe L . Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355(9208):949-55. View

Ang K, Trotti A, BROWN B, Garden A, Foote R, Morrison W . Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 51(3):571-8. DOI: 10.1016/s0360-3016(01)01690-x. View

AWWAD H, Lotayef M, Shouman T, BEGG A, Wilson G, Bentzen S . Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer. 2002; 86(4):517-23. PMC: 2375281. DOI: 10.1038/sj.bjc.6600119. View

Rosenthal D, Liu L, Lee J, Vapiwala N, Chalian A, Weinstein G . Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck. 2002; 24(2):115-26. DOI: 10.1002/hed.10038. View

Smid L, Budihna M, Zakotnik B, Soba E, Strojan P, Fajdiga I . Postoperative concomitant irradiation and chemotherapy with mitomycin C and bleomycin for advanced head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2003; 56(4):1055-62. DOI: 10.1016/s0360-3016(03)00207-4. View

Cooper J, Pajak T, Forastiere A, Jacobs J, Campbell B, Saxman S . Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350(19):1937-44. DOI: 10.1056/NEJMoa032646. View

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre J, Greiner R . Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350(19):1945-52. DOI: 10.1056/NEJMoa032641. View

Sanguineti G, Richetti A, Bignardi M, Corvo R, Gabriele P, Sormani M . Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. Int J Radiat Oncol Biol Phys. 2005; 61(3):762-71. DOI: 10.1016/j.ijrobp.2004.07.682. View

Bernier J, Cooper J, Pajak T, Van Glabbeke M, Bourhis J, Forastiere A . Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27(10):843-50. DOI: 10.1002/hed.20279. View

10.

Laramore G, Scott C, Al-Sarraf M, Haselow R, Ervin T, Wheeler R . Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992; 23(4):705-13. DOI: 10.1016/0360-3016(92)90642-u. View

11.

Bonner J, Harari P, Giralt J, Azarnia N, Shin D, Cohen R . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78. DOI: 10.1056/NEJMoa053422. View

12.

Argiris A, Karamouzis M, Johnson J, Heron D, Myers E, Eibling D . Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer. Laryngoscope. 2007; 118(3):444-9. DOI: 10.1097/MLG.0b013e31815b48f4. View

13.

Cognetti D, Weber R, Lai S . Head and neck cancer: an evolving treatment paradigm. Cancer. 2008; 113(7 Suppl):1911-32. PMC: 2751600. DOI: 10.1002/cncr.23654. View

14.

Cooper J, Zhang Q, Pajak T, Forastiere A, Jacobs J, Saxman S . Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012; 84(5):1198-205. PMC: 3465463. DOI: 10.1016/j.ijrobp.2012.05.008. View

15.

Martins R, Parvathaneni U, Bauman J, Sharma A, Raez L, Papagikos M . Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013; 31(11):1415-21. DOI: 10.1200/JCO.2012.46.3299. View

16.

Maxwell J, Ferris R, Gooding W, Cunningham D, Mehta V, Kim S . Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer. 2013; 119(18):3302-8. DOI: 10.1002/cncr.28169. View

17.

Kunieda F, Kiyota N, Tahara M, Kodaira T, Hayashi R, Ishikura S . Randomized phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck: Japan Clinical Oncology Group Study (JCOG1008). Jpn J Clin Oncol. 2014; 44(8):770-4. DOI: 10.1093/jjco/hyu067. View

18.

Harari P, Harris J, Kies M, Myers J, Jordan R, Gillison M . Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014; 32(23):2486-95. PMC: 4121506. DOI: 10.1200/JCO.2013.53.9163. View

19.

Ang K, Zhang Q, Rosenthal D, Nguyen-Tan P, Sherman E, Weber R . Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014; 32(27):2940-50. PMC: 4162493. DOI: 10.1200/JCO.2013.53.5633. View

20.

Mesia R, Henke M, Fortin A, Minn H, Yunes Ancona A, Cmelak A . Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015; 16(2):208-20. DOI: 10.1016/S1470-2045(14)71198-2. View